⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7499836 | 1.00 | — | — | |
| SCHEMBL7501306 | 0.84 | — | — | |
| SCHEMBL7501312 | 0.84 | — | — | |
| SCHEMBL17732224 | 0.83 | — | — | |
| SCHEMBL10965368 | 0.78 | — | — | |
| SCHEMBL7501895 | 0.78 | — | — | |
| SCHEMBL7504540 | 0.78 | — | — | |
| SCHEMBL9860946 | 0.77 | RIPK1 (0.31) | — | |
| SCHEMBL11093784 | 0.73 | — | — | |
| SCHEMBL16315614 | 0.73 | SMN1; SMN2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6380215-B1 | FOR PREVENTION AND/OR TREATMENT OF DISEASES CAUSED BY THROMBUS FORMATION SUCH AS ARTERIAL THROMBOSIS, ARTERIAL SCLEROSIS, ISCHEMIC HEART DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2002-04-30 | — | — | US | disclosed |
| US-20010051730-A1 | Beta-alanine derivative and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-13 | — | — | US | disclosed |
| EP-0669912-B1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-12-05 | — | — | EP | disclosed |
| EP-1106606-A2 | N-(3-piperidinylcarbonyl)-beta-alanine derivatives as paf antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-13 | — | — | EP | disclosed |
| CN-1041919-C | N-(3-piperidinylcarbonyl)-beta-alanine derivatives as PAF antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-02-03 | — | — | CN | disclosed |
| CN-1116847-A | N- (3-piperidinylcarbonyl) -beta-aminopropionic acid derivatives as PAF antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-02-14 | — | — | CN | disclosed |
| EP-0669912-A1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-06 | — | — | EP | disclosed |
| WO-1995008536-A1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-30 | — | — | WO | disclosed |
| EP-0001627-B1 | 3-SUBSTITUTED-6-(1'HYDROXETHYL)-7-OXO-1-AZABICYCLO(3.2.0.)-HEPT-2-ENE-2-CARBOXYLIC ACID, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | MERCK & CO. INC. (US) | 1984-04-04 | — | — | EP | disclosed |
| EP-0001627-A1 | 3-Substituted-6-(1'hydroxethyl)-7-oxo-1-azabicyclo(3.2.0.)-hept-2-ene-2-carboxylic acid, its preparation and pharmaceutical compositions containing it | MERCK & CO. INC. (US) | 1979-05-02 | — | — | EP | disclosed |